IMMUNE EFFECTOR MECHANISMS IN EBV CARRYING PATIENTS

EBV 携带患者的免疫效应机制

• 批准号: 3169165
• 负责人: GEORGE KLEIN
• 金额: $ 12.08万
• 依托单位: KAROLINSKA INSTITUTE
• 依托单位国家: 美国
• 财政年份: 1981
• 资助国家: 美国
• 起止时间: 1981-09-01 至 1988-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3169165
• 关键词: B lymphocyte; Burkitt's lymphoma; Epstein Barr virus; Hodgkin's disease; acquired immunodeficiency; antibody formation; cell mediated cytotoxicity; human subject; humoral immunity; immune adherence reaction; immunodeficiency; immunoregulation; latent virus infection; lymphokines; lymphoma; migration inhibition factor; mixed tissue /cell culture; monoclonal antibody; mononucleosis; neoplasm /cancer immunology; neoplasm /cancer remission /regression; serology /serodiagnosis; sex linked trait; transforming virus; virus antigen; virus diseases; virus replication

This project deals with the interactions between EBV-infected cells and the host immune system in normal and immunodefective persons. For an improved understanding of this complex system, it is necessary to broaden our knowledge both on the interaction of the virus with different host cells in vitro and in vivo, and on the interplay between the virally infected cells and the host. This project aims at the analysis of certain questions at both levels, in a mutually interrelated way. The project consists of the following parts: I. Analysis of the virus-cell-host system II. Clinically related studies Antigenic analysis will focus on the role of the newly detected membrane antigen on the surface of transformed, proliferating, non-virus producer cells, its immune recognition, its genetic determination mechanism (in relation to the viral genome) and the significance of blocking antibodies directed against it. Effector analysis will disssect the role of various lymphocyte subtypes and mediators in BL and NPC, immunodefectives with and without EBV-carrying lymphoproliferative disease, and in healthy controls. At the target cell level, continued attention will be given to the role of spontaneous or induced B-cell differentiation by immunological and non-immunological host control. The clinically related studies wil focus on the monoclonal vs. polyclonal nature of EBV-transformed B-cell proliferation in transplant lymphomas, and lymphoproliferative disease in XLP, as it relates to EBV. At the effector level, we shall continue to investigate the impairment of different effectors and the role of suppression in immunodeficient EBV-carrying lymphomas, as contrasted to immunodefective states (HD and NHL, AT) with an impaired control of EBV-transformed cells (as indicated by the dissociation of sensitization and antibody formation into EBNA, on the one hand, and to EA/VCA on the other), but without EBV carryig lymphoproliferative disease. A special effector and target cell study will be carried out on pre-AIDS lymphomas.

这个项目研究了EBV感染细胞和 正常人和免疫缺陷者的宿主免疫系统。为了更好地 了解这个复杂的系统，有必要拓宽我们的视野 关于病毒与不同宿主细胞相互作用的知识 体外和体内，以及病毒感染细胞之间的相互作用 和主持人。该项目旨在分析以下几个问题 这两个层面，以相互关联的方式。 该项目由以下部分组成： 一、病毒-细胞-宿主系统的分析 二、临床相关研究 抗原分析将重点放在新检测到的膜的作用上 转化、增殖、非病毒产生者表面抗原 细胞，其免疫识别，其遗传决定机制(in 与病毒基因组的关系)和封闭抗体的意义 是针对它的。效应器分析将剖析不同的角色 免疫缺陷合并鼻咽癌和鼻咽癌患者外周血中淋巴细胞亚群和介质的研究 没有携带EB病毒的淋巴增生性疾病，以及健康对照组。 在目标单元一级，将继续关注 自发性或诱导B细胞分化的免疫学和 非免疫性寄主控制。 临床相关研究将集中在单克隆型与多克隆型。 移植淋巴瘤中EB病毒转化的B细胞增殖的性质， 和XLP的淋巴增生性疾病，因为它与EBV有关。在 效应器水平，我们将继续调查损害 不同效应物及其抑制在免疫缺陷中的作用 EBV携带性淋巴瘤与免疫缺陷状态(HD和 NHL，AT)对EBV转化细胞的控制受损(如以下所示 致敏和抗体形成在EBNA中的分离，关于 一方面是EA/VCA)，但没有EBV携带者 淋巴增生性疾病。 将对艾滋病前病毒进行特殊效应和靶细胞研究 淋巴瘤。